Glipizide
A sulfonylurea medication that lowers blood sugar in type 2 diabetes by promoting insulin secretion from pancreatic beta cells in response to meals. It has also been investigated for potential benefits in cardiovascular risk management and atrial fibrillation prevention. Extended-release formulations provide smoother blood glucose control throughout the day.
Khối lượng phân tử
445,5000 g/mol
LogP
1,90
TPSA
139,00 Ų
Lipinski RO5
Đạt
Lĩnh vực điều trị
Cơ chế tác dụng
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
InChI
InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
Molecular Formula
C21H27N5O4S
HBD / HBA
3 / 6
Liên kết có thể quay
7
Nguyên tử nặng
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A sulfonylurea medication that lowers blood sugar in type 2 diabetes by promoting insulin secretion from pancreatic beta cells in response to meals. It has also been investigated for potential benefits in cardiovascular risk management and atrial fibrillation prevention. Extended-release formulations provide smoother blood glucose control throughout the day.
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Yes, Glipizide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1073. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3478. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="glipizide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/glipizide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/glipizide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/glipizide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="glipizide"></drugfyi-drug>